返回
李娟娟 (Juanjuan Li)
lanzhou jiaotong university
54H指数
620论文数
1.1W被引数
收录论文 134
发表时间
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysisanti-PD-1抗体camrelizumab联合VEGFR-2抑制剂阿帕替尼和化疗作为三阴性乳腺癌新辅助治疗的探索性II期试验 (NeoPanDa03): 疗效,安全性和生物标志物分析

